What Rangar treats: Main Uses and Benefits

The key purpose of Rangar is to provide focused, short-term support for managing specific domains of symptomatic discomfort and instability. Rangar is primarily used to address symptoms related to physical discomfort in conditions associated with acute or disruptive episodes. It is applied when certain patterns of symptoms become heightened or disruptive, aiming to ease the patient's immediate burden and contribute to easing the overall symptom load.

---

Easing Periods of Heightened Symptomatic Discomfort

This therapeutic application covers use in situations involving conditions characterized by periods of heightened symptoms, such as the chest pain associated with chronic angina. It is applied in clinical settings that involve acute or unstable symptom patterns, helping to address groups of symptoms that may become intense or disruptive. The benefit offers symptomatic relief that helps patients cope more steadily with difficult episodes.

Support for Episodic Functional Strain

Rangar is commonly used across conditions characterized by episodic or fluctuating symptom patterns, where symptoms create noticeable physiological strain and interfere with daily functioning. It is relevant when supportive symptom management is appropriate, as it is applied across domains where additional symptomatic support is needed, and helps improve day-to-day comfort during symptomatic periods.

---

Quick Fact: Support for Angina-Related Discomfort Rangar is used for managing symptoms associated with chronic angina, providing supportive relief during periods of increased distress or discomfort.

Regulatory References

1. MedlinePlus Drug Information on Ranolazine

Rangar is approved for use in adults aged 18 years and older. The medicine's official eligibility profile is strictly defined by regulatory documents, primarily focusing on liver function and concurrent medication use. The medicine is contraindicated (must not be used) in several key patient populations. This includes individuals with severe hepatic impairment or those with known hypersensitivity to rasagiline. Absolute prohibition also extends to patients taking any other MAO inhibitor, including over-the-counter products like St. John’s Wort, as well as the medicines Pethidine or Dextromethorphan.

Eligibility Status	Patient Group / Condition
Contraindicated	Severe hepatic impairment; Known hypersensitivity; Concomitant use with MAO inhibitors (including St. John’s Wort), Pethidine, or Dextromethorphan.
Not Recommended	Pediatric population (under 18 years), as safety and efficacy are not established; Use is preferably avoided during pregnancy.
Restricted Use	Mild hepatic impairment (requires a reduced maximum dose); Patients taking Ciprofloxacin or other strong CYP1A2 inhibitors (requires a reduced maximum dose).

For pregnant women, use is preferably avoided due to a lack of clinical data. Use in breastfeeding mothers requires caution as non-clinical data suggests the medicine may inhibit milk secretion. Patients with mild to moderate renal impairment do not require a dose adjustment.

Rangar is known to have significant interactions with certain other medicines, medicinal products, and substances, which necessitates careful consideration and potential dose adjustments by a healthcare professional. These interactions primarily involve changes to how Rangar is processed by the body (pharmacokinetic interactions) and may alter the effectiveness or safety profile of either Rangar or the co-administered agent.

Interacting Agents and Drug Classes

Category	Specific Examples	Nature of Interaction
Strong CYP3A4 Inhibitors	Ketoconazole, Itraconazole, Clarithromycin, Ritonavir	Significantly increase Rangar concentration in the blood, raising the risk of dose-related adverse effects. Co-administration is generally contraindicated or requires strict medical supervision and dose reduction.
Strong CYP3A4 Inducers	Rifampin, Carbamazepine, Phenytoin, St. John's Wort	Substantially decrease Rangar concentration in the blood, which can lead to reduced efficacy or treatment failure. Co-administration should be avoided.
P-gp Inhibitors	Cyclosporine, Verapamil	May increase Rangar absorption and subsequent exposure, increasing the risk of adverse reactions. Requires cautious use and monitoring.
Grapefruit Juice	N/A	Inhibits gut enzymes, leading to increased Rangar exposure. Consumption should be avoided during treatment.

Management and Restrictions

The most significant interaction involves potent inhibitors of the CYP3A4 enzyme, which are contraindicated for concurrent use due to the risk of dangerously elevated drug levels. Conversely, CYP3A4 inducers should be avoided because they can lead to sub-therapeutic levels of Rangar. For combinations requiring close monitoring, the timing of administration or the dosage of Rangar may need precise modification to maintain a safe and effective therapeutic range. Patients must inform their provider of all medicines, supplements, and herbal products before starting Rangar.

Selective and Irreversible Enzyme Blockade

Rangar exerts its action by forming a permanent, covalent bond with the Monoamine oxidase type B (MAO-B) enzyme, a highly selective process that leads to the irreversible inactivation of the enzyme molecule. This mechanism ensures that the pharmacological consequence is sustained until the body can synthesize new, functional MAO-B to replace the inhibited molecules.

---

Modulation of Dopamine Catabolism

The physiological consequence of MAO-B blockade is the prevention of the oxidative catabolism of the existing supply of the neurotransmitter dopamine within the central nervous system. By reducing this metabolic breakdown pathway, the drug increases the extracellular concentration of dopamine in the striatum, which in turn augments dopaminergic signaling in circuits linked to motor function.

---

Mechanism Constraints

The drug’s effect is intrinsically constrained by the remaining functional capacity of endogenous dopaminergic neurons, as the mechanism depends on preserving synthesized dopamine rather than stimulating new production. Additionally, the essential selectivity for MAO-B over MAO-A can be lost at doses that exceed the threshold, limiting the targeted nature of the mechanism.

How to Use Rangar

Administration of Rangar (rasagiline mesylate) is based on specific guidelines focusing on consistent daily use and dose limits. The medicine is consistently administered via the oral route as an immediate-release tablet.

Dosing and Frequency Patterns

The standard approach to using Rangar requires once-daily administration, and the medicine may be taken with or without food. The maximum approved dose is 1 mg per day, which should not be exceeded.

Usage Scenario	Starting/Maintenance Dose	Maximum Daily Dose
Monotherapy (alone)	1 mg once daily	1 mg
Adjunct to Levodopa	0.5 mg once daily (initial), adjustable to 1 mg	1 mg

Population and Contextual Adjustments

Specific dosage modifications are formalized for certain clinical contexts. Individuals with mild hepatic impairment are instructed to use a dose that does not exceed 0.5 mg daily. This lower daily dose is also mandatory if Rangar is used concurrently with potent inhibitors of the CYP1A2 enzyme, such as ciprofloxacin.

No dose adjustment is required for older adults or individuals with any degree of renal impairment. The overall treatment is intended for chronic, long-term management. If a dose is missed, the standard procedure is to skip the missed dose and take the next dose at the usual scheduled time, rather than taking two doses simultaneously.

Research evidence / Overview of studies for Rangar

---

1. Evidence for Initial Monotherapy in Early Parkinson's Disease

The evidence base for Rangar's use as an initial, stand-alone treatment for Parkinson's disease (PD) is primarily drawn from short-term, randomized, double-blind, placebo-controlled clinical trials. These studies focused on adults with early-stage PD who were not yet receiving other major treatments. Researchers examined changes in outcomes related to physical discomfort and daily functioning, using standardized clinical rating scales to measure symptom severity over time. Some trials also monitored the time elapsed until other antiparkinsonian medications were subsequently initiated, which provided another outcome related to the functional status.

2. Evidence as Adjunctive Therapy Alongside Levodopa

Rangar was studied for use as an add-on treatment for people with more advanced PD who were already taking levodopa and experiencing periods of fluctuating symptom control. These fluctuations are often categorized as "Off" time (when symptoms return) and "On" time (when control is better). The primary outcomes reflecting daily functioning or activity level were monitored in these trials using patient-reported diaries. Research examined measurements of change in the average total daily "Off" time when Rangar was introduced alongside levodopa, compared to adding a placebo. Findings across different studies were largely similar in describing these changes, contributing to the broader evidence landscape for contributing to research on these specific fluctuations.

3. Long-Term Data and Follow-up Assessments

Researchers also conducted extended research to understand how symptoms evolved in the observed populations over longer time intervals, including open-label extension studies that followed participants for several years. Specialized delayed-start trial designs were implemented to explore the distinction between a short-term symptomatic effect and a long-term functional effect. However, long-term effects are not fully established by continuous, randomized, placebo-controlled methods. Open-label follow-up provided data on how patients' changes in functional measures were observed over extended periods.

4. What Remains Uncertain About Rangar

The existing research provides context but not individual predictions, and certain questions about the long-term course of the condition remain uncertain. The follow-up durations were limited in the strictly controlled trials, and the complex nature of the specialized delayed-start designs has led to varied interpretations of the ultimate findings. Additionally, evidence quality varies across studies when assessing non-motor outcomes related to systemic or functional imbalance (e.g., fatigue, sleep, mood) compared to the well-studied motor outcomes.

Common questions about Rangar (FAQ)

Q: Are there different strengths or doses of Rangar available?

Rangar is supplied in two different tablet strengths, specifically 0.5 mg and 1 mg. The strength used is determined based on the patient's treatment plan and any concurrent use with other medicines, as described in official prescribing information.

Q: Is Rangar a type of narcotic or controlled substance?

Rangar is not regulated as a controlled substance under the US Controlled Substances Act. It is not listed as a narcotic by the Drug Enforcement Administration (DEA).

Q: What is the purpose of the Boxed Warning (Black Box Warning) on Rangar?

According to the official FDA prescribing information for Rangar, the medicine does not currently contain a Boxed Warning (also known as a Black Box Warning). This is a specialized regulatory communication used to highlight significant risks.

Q: How long does Rangar stay in your system after taking it?

The half-life, which measures how quickly the medicine is cleared from the bloodstream, is approximately 3 hours. However, the medicine works by causing an irreversible change to the MAO-B enzyme, meaning its therapeutic effect lasts longer than the time it stays in the blood.

Q: Is it okay to drive or operate heavy machinery while on Rangar?

Official safety warnings caution against driving or performing hazardous tasks when initiating Rangar treatment. Because the medicine can cause sudden sleepiness or dizziness, patients are advised to wait before performing these activities until the effects on their alertness and motor skills are known.

Q: Does Rangar change how I metabolize (process) alcohol?

Consuming alcohol while taking this medicine should be avoided or limited. Official documents state that alcohol may increase certain side effects of Rangar, such as dizziness and drowsiness.

Q: Do lifestyle changes affect how well Rangar works?

Yes, diet is a critical lifestyle factor that affects Rangar. Because Rangar belongs to the MAO-B inhibitor class, official documents indicate that patients must avoid consuming foods that are high in tyramine, such as aged cheese and cured meats, to manage the risk of dangerously high blood pressure.

Q: Can Rangar cause problems with sleep?

Official product information states that Rangar may affect sleep patterns. It is associated with insomnia, abnormal dreams, and daytime drowsiness (somnolence), including the possibility of falling asleep during normal activities.

Q: Does Rangar affect blood pressure?

The official labeling indicates that Rangar can affect blood pressure in two different ways. It may cause abnormally high blood pressure (hypertension) or cause an excessive drop in blood pressure when standing up (orthostatic hypotension).

Q: What are the general rules for stopping Rangar treatment?

Regulatory guidance states that treatment should not be stopped abruptly. Doing so can cause serious withdrawal-emergent symptoms, such as fever and confusion. All discontinuation must be discussed with and guided by a healthcare provider.

Q: Is there a risk of dependence or withdrawal with Rangar?

Rangar has a defined risk of withdrawal-emergent symptoms if treatment is stopped suddenly. These symptoms can include high fever and confusion, making supervised discontinuation necessary.

Q: Does Rangar affect fertility in men or women?

Non-clinical animal studies have shown that Rangar may impair fertility. However, the effect of the medicine on human fertility in men and women is not yet known or established.

Q: Is Rangar used for anything besides the main condition it treats?

According to the official product information, the medicine is only approved and indicated for the treatment of Parkinson's disease. This includes using it alone (monotherapy) or as an add-on (adjunct) treatment with levodopa.

Q: Is there a generic version of Rangar available?

Yes, a generic version is available. The active ingredient, rasagiline mesylate, is available in generic form.

Q: Can Rangar be taken with common over-the-counter pain relievers?

Official patient information advises reporting all medicines, including common over-the-counter pain relievers (analgesics), before starting Rangar. This is due to the potential for drug-drug interactions that must be considered.

Q: Can Rangar be taken at the same time as my daily vitamins or supplements?

While specific daily vitamins may not be listed as an interaction, patients are advised to disclose all supplements and herbal products to their healthcare provider. Certain products can change the medicine's levels in the body, which could affect its safety or effectiveness.

Q: Can Rangar be taken if I have a history of heart issues?

Official warnings state that Rangar is associated with the risk of developing both high and low blood pressure. Patients with a history of heart issues may require close monitoring by a healthcare provider while using this medicine.

Q: Is weight gain a possible side effect of Rangar?

Weight changes have been noted in research and adverse reaction reports. While weight loss is listed as an adverse reaction in clinical data, weight gain has also been reported in post-market surveillance, though its frequency is not well-established.

Q: What are the signs of an allergic reaction to Rangar?

Serious allergic reactions, known as hypersensitivity, can occur with this medicine. Regulatory information describes signs that require immediate medical help, which include hives, difficulty breathing, and swelling of the face, lips, tongue, or throat.

Q: Why do people sometimes stop taking Rangar?

Reasons for stopping the medicine may include the occurrence of severe or serious adverse reactions. Official documents cite examples such as uncontrolled blood pressure, severe low blood pressure, or the new occurrence or worsening of melanoma.

Q: Are the research studies on Rangar ongoing or completed?

The main studies used for initial regulatory approval of the medicine are completed. However, regulatory authorities and researchers often conduct follow-up and long-term surveillance studies, which may be ongoing under different protocols.

Q: What should I do if a side effect of Rangar seems minor?

Official guidance suggests contacting a healthcare provider or pharmacist to report any suspected adverse reactions, regardless of how minor they may seem. This helps ensure safety is continually monitored by health authorities.

The storage and disposal of Rangar (Rasagiline mesylate) must strictly adhere to the requirements documented on the official labeling to ensure product stability and safety.

Storage Conditions

Rangar must be stored at Controlled Room Temperature, specifically 20^circ to 25 C (68^circ to 77 F). The container must be tight, light-resistant, and kept tightly closed to protect the medicine from light, moisture, and excess heat. The product must also be kept out of the sight and reach of children, utilizing a child-resistant closure as required by the drug label.

Disposal Instructions

To dispose of unused or expired Rangar, the preferred method is to utilize a drug take-back program or a prepaid drug mail-back envelope. If these options are not available, tablets should be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. Do not flush Rangar unless the official regulatory documentation explicitly instructs this action.